Aethlon Medical, Inc., a medical therapeutic company, engages in developing novel immunotherapeutic devices in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device intended to address unmet needs in oncology, life-threatening infectious diseases, organ transplantation, and other disease states. The company was founded in 1984 and is based in San Diego, California.…
Aethlon Medical Reports Second Quarter Fiscal 2027 Results and Provides Corporate Update
Aethlon Medical (NASDAQ: AEMD) is listed on Nasdaq, where its shares trade in USD. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 9 employees.
The shares were at 5.460 USD on 20 November 2026, down 74.4% over 52 weeks. Its 52-week range is 1.410 USD to 25.65 USD: the price is 78.7% below the high and 287.2% above the low.
Its market capitalisation is 8.78M USD.
Aethlon Medical reports return on equity of -146.4% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 4.57M USD. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. 2 analysts cover the stock; their mean price target of 13.25 USD is 142.7% above the current price. The next earnings report is expected on 11 February 2027.